Patexia. Community

Innovation, Technology, and IP News

Second Chances From the Second Circuit: Tiffany’s $21m Judgment Is Overturned and Remanded Back to the SDNY

The U.S. Court of Appeals in the Second Circuit found in favor of Costco in the latest chapter of an over seven-year legal battle between Tiffany and Co...

White House Pushes Back on PTAB Rule Making Effort

Agency to Consider Further Public Comment Over the past few months, Congress has been asked to investigate the Patent Trial & Appeal Board’s (PTAB) practice of denying AIA...

Patent Litigation Up 23 Percent in Q3

The third quarter of 2020 is over and despite the pandemic, so far this year has been one of the more active years for patent litigation. District court patent litigation was up 23...

Fresh From the Bench: Latest Federal Circuit Court Cases

CASE OF THE WEEK Immunex Corp. v. Sanofi-Aventis U.S. LLC, Appeal Nos. 2019-1749, -1777 (Fed. Cir. Oct. 13, 2020) In our Case of the Week, the Federal Circuit addressed the...

Feed tagged as "patent prosecution":
Update: After publishing this article on October 7, 2020, several law firms reached out to confirm their actual patent prosecution revenue which helped us discover a... Read More »
Coronavirus and its global impact have affected almost every sector of the economy. With all of the job losses and the continued lockdown in more than 80% of US... Read More »
We released our first patent prosecution rankings for the top 1,000 patent firms back in March, which was based on the activity, efficiency and success rates of more... Read More »
Three years ago, we started publishing the Patexia Insight Series with our first article about the Shortage of Patent Attorneys in the U.S. A lot has changed since... Read More »
Foreword: To date, the BigPatentData Blog has given little no attention to design patents. This is because I barely know the difference between a design... Read More »
In my previous post, I looked at two metrics - allowance rate and actions per disposal - that I find useful in assessing an examiner and formulating a strategy for... Read More »
A few weeks ago, we published the top five fastest growing patent firms. We also talked about the challenges the sector is facing and some of the concerns of law... Read More »
No, my site did not get overrun by the pharmaceutical pushers that like to submit "advice" in the comments section. The title is referring to entity size... Read More »
Below is an animated visualization of the subject matter eligibility 101 roller coaster that patent prosecutors and examiners have been on over the past 5 years. The... Read More »
Last Wednesday, we released our  Patent Prosecution Intelligence Report for 2019, where we have ranked the top 1,000 most active and best performing patent firms ... Read More »
A few weeks ago we published an article (Patexia Insight 54), explaining why patent prosecution is becoming commoditized  and why some of the AM LAW 100 are... Read More »
A few weeks ago, we discussed how patent prosecution practice is becoming commoditized. Since then, a number of firms and attorneys have contacted us and explained... Read More »
Comments
Anonymous "we should expect an allowance rate of about 90% for him based on the stats we have from A1."
Feb 3, 2019
Anonymous I do not see what is useful about this information (maybe I am missing something).
Feb 3, 2019
As we prepare to release our first Patent Prosecution Intelligence Report, we have been hearing from many of practitioners that it is getting much harder to run a... Read More »
On April 25th, a Fed. Cir. panel of Judges Taranto, Clevenger and Chen affirmed the unenforceability of two Merck patents covering a drug presently marketed as... Read More »
Continuation Applications & Terminal Disclaimers: Infectious Estoppel Patent owner estoppel is codified by Patent Trial & Appeal Board (PTAB) regulation... Read More »
Prosecutor’s Tool Box 2017 Patent prosecutors navigate complex USPTO rules and seemingly esoteric examinational requirements to procure patent rights. In... Read More »
In Regeneron Pharmaceuticals v. Merus N.V., [16-1346] the Federal Circuit denied rehearing and rehearing en banc the July panel decision, previously discussed here... Read More »
Broadest Reasonable Does not Mean Broadest Possible! The USPTO applies a broadest reasonable claim interpretation (BRI) to patents and patent applications. The... Read More »
What Exactly is the "Thrust of the Rejection?" Every so often a decision comes out of the USPTO's Patent Trial & Appeal Board (PTAB) or the... Read More »
Are You Properly Corroborating Your In Re Katz Declarations? Every so often a decision comes out of the USPTO's Patent Trial & Appeal Board (PTAB) or the... Read More »
Show more Newsfeed posts